中华肿瘤杂志
中華腫瘤雜誌
중화종류잡지
CHINESE JOURNAL OF ONCOLOGY
2012年
1期
68-72
,共5页
钟国成%张小玉%陈健%孙薏%张文华%桂永忠%龙海霞%朱波
鐘國成%張小玉%陳健%孫薏%張文華%桂永忠%龍海霞%硃波
종국성%장소옥%진건%손의%장문화%계영충%룡해하%주파
胰腺肿瘤%高强度聚焦超声%超声造影%吉西他滨%动脉灌注
胰腺腫瘤%高彊度聚焦超聲%超聲造影%吉西他濱%動脈灌註
이선종류%고강도취초초성%초성조영%길서타빈%동맥관주
Pancreatic neoplasms%High intensity focused ultrasound%Ultrasonic contrast imaging%Gemcitabine%Intra-arterial infusion
目的 探讨高强度聚焦超声(HIFU)联合吉西他滨动脉灌注治疗中晚期胰腺癌的临床疗效和影像学评估方式.方法 48例诊断明确的胰腺癌患者被随机分为两组:HIFU组24例,给予单纯HIFU治疗；联合组24例,除HIFU治疗外,还给予吉西他滨动脉灌注化疗.观察两组患者的临床疗效.结果 联合组肿瘤血供比HIFU组减少(P＜0.05).治疗后3个月,联合组的PS评分、视觉模拟评分、总胆红素、血清糖类抗原(CA)-199水平、CA-242水平和癌胚抗原水平[分别为1.40±0.88、1.73±1.57、(61.38±18.19) μmol/L、(77.56±25.73) U/ml、( 64.75±24.82) U/ml和(19.75±10.64) ng/ml]均优于HIFU组[分别为1.94 ±1.05、2.72±1.83、(97.65±20.63) μmol/L、( 114.87±32.48) U/ml、(85.24 ±21.94) U/ml和(27.24±10.83) ng/ml,均P＜0.05].治疗后6个月,联合组患者预后指标优于HIFU组(P＜0.05).联合组患者的1年生存率、中位生存时间、中位疾病进展时间(分别为66.66％、16.72个月、10.54个月)均优于HIFU组(分别为41.66％、10.95个月、7.38个月,P ＜0.05).结论 超声造影技术联合CT及肿瘤标志物可以用于评价HIFU治疗胰腺癌的疗效.HIFU联合吉西他滨可提高胰腺癌患者的临床疗效和远期生存率.
目的 探討高彊度聚焦超聲(HIFU)聯閤吉西他濱動脈灌註治療中晚期胰腺癌的臨床療效和影像學評估方式.方法 48例診斷明確的胰腺癌患者被隨機分為兩組:HIFU組24例,給予單純HIFU治療；聯閤組24例,除HIFU治療外,還給予吉西他濱動脈灌註化療.觀察兩組患者的臨床療效.結果 聯閤組腫瘤血供比HIFU組減少(P＜0.05).治療後3箇月,聯閤組的PS評分、視覺模擬評分、總膽紅素、血清糖類抗原(CA)-199水平、CA-242水平和癌胚抗原水平[分彆為1.40±0.88、1.73±1.57、(61.38±18.19) μmol/L、(77.56±25.73) U/ml、( 64.75±24.82) U/ml和(19.75±10.64) ng/ml]均優于HIFU組[分彆為1.94 ±1.05、2.72±1.83、(97.65±20.63) μmol/L、( 114.87±32.48) U/ml、(85.24 ±21.94) U/ml和(27.24±10.83) ng/ml,均P＜0.05].治療後6箇月,聯閤組患者預後指標優于HIFU組(P＜0.05).聯閤組患者的1年生存率、中位生存時間、中位疾病進展時間(分彆為66.66％、16.72箇月、10.54箇月)均優于HIFU組(分彆為41.66％、10.95箇月、7.38箇月,P ＜0.05).結論 超聲造影技術聯閤CT及腫瘤標誌物可以用于評價HIFU治療胰腺癌的療效.HIFU聯閤吉西他濱可提高胰腺癌患者的臨床療效和遠期生存率.
목적 탐토고강도취초초성(HIFU)연합길서타빈동맥관주치료중만기이선암적림상료효화영상학평고방식.방법 48례진단명학적이선암환자피수궤분위량조:HIFU조24례,급여단순HIFU치료；연합조24례,제HIFU치료외,환급여길서타빈동맥관주화료.관찰량조환자적림상료효.결과 연합조종류혈공비HIFU조감소(P＜0.05).치료후3개월,연합조적PS평분、시각모의평분、총담홍소、혈청당류항원(CA)-199수평、CA-242수평화암배항원수평[분별위1.40±0.88、1.73±1.57、(61.38±18.19) μmol/L、(77.56±25.73) U/ml、( 64.75±24.82) U/ml화(19.75±10.64) ng/ml]균우우HIFU조[분별위1.94 ±1.05、2.72±1.83、(97.65±20.63) μmol/L、( 114.87±32.48) U/ml、(85.24 ±21.94) U/ml화(27.24±10.83) ng/ml,균P＜0.05].치료후6개월,연합조환자예후지표우우HIFU조(P＜0.05).연합조환자적1년생존솔、중위생존시간、중위질병진전시간(분별위66.66％、16.72개월、10.54개월)균우우HIFU조(분별위41.66％、10.95개월、7.38개월,P ＜0.05).결론 초성조영기술연합CT급종류표지물가이용우평개HIFU치료이선암적료효.HIFU연합길서타빈가제고이선암환자적림상료효화원기생존솔.
Objective The aim of this study was to discuss the clinical effectiveness of high intensity focused ultrasound (HIFU) combined with gemcitabine administered by intra-arterial infusion on intermediate and advanced pancreatic cancer. Methods Forty-eight patients with intermediate and advanced pancreatic cancer were divided into two groups.Twenty-four patients of the experimental group were treated by HIFU combined with gemcitabine,and 24 patients of the the HIFU group were treated by HIFU alone.Then the curative effect,extent of pain relief,and survival time were compared in the course of the treatment between the two groups.Results As compared with those in the control group,the overall response rate,level of pain relief,and 12-month survival rate after therapy were higher and the median survival time was longer in the joint group ( P ＜ 0.05 ).Conclusions Ultrasound imaging,CT and associated tumor marker detection can make effective measurement to evaluate curative effect on pancreatic carcinoma. HIFU plus gemcitabine administered by intra-arterial infusion can improve the clinical therapeutic efficacy,pain relief,quality of life and long-term survival rate of patients with pancreatic cancer.
